P21 5 MG

Dragon Pharma P21 5 mg – Synthetic CNTF-Derived Peptide for Neurogenesis Research

Dragon Pharma P21 5 mg is a synthetic, lipophilic tetrapeptide derived from ciliary neurotrophic factor (CNTF). This compound, also known as P021, has been designed to cross the blood-brain barrier and is studied in preclinical models for its potential to promote neurogenesis, increase brain-derived neurotrophic factor (BDNF) levels, and support synaptic plasticity in the context of neurodegenerative conditions such as Alzheimer's disease.

Each vial contains 5 mg of lyophilized P21 in a 2 mL format, requiring reconstitution with bacteriostatic water before use. The unique lipophilic properties of P21 enable effective CNS penetration, making it a valuable tool for investigating neuroregenerative mechanisms and cognitive function in research settings. For related research compounds, explore our peptides category and specifically Semax for complementary neuropeptide research applications.

What Makes P21 Valuable in Research?

P21 represents a focused approach to studying neurotrophic signaling and neurogenesis. By mimicking key functional domains of CNTF while maintaining a small, lipophilic structure, this peptide offers improved CNS bioavailability compared to larger neurotrophic factors. Its ability to enhance BDNF expression and support synaptic plasticity provides researchers with a tool to investigate the molecular pathways underlying learning, memory, and neural repair.

Researchers value P21 for its targeted mechanism and practical research applications. Its small size and blood-brain barrier penetration capabilities make it suitable for various experimental designs, from in vitro neuronal culture studies to in vivo models of cognitive function and neurodegeneration. For investigators exploring other neuroprotective compounds, DIHEXA 5 mg offers complementary research avenues in synaptic enhancement and cognitive function.

Current scientific literature on P21 and related neurotrophic peptides can be accessed through the PubMed database, where researchers can review peer-reviewed studies on its biological activity and experimental applications.

Key Research Applications for Dragon Pharma P21

• ✔ Investigation of neurogenesis and neural stem cell differentiation
• ✔ Evaluation of BDNF expression and signaling pathways
• ✔ Research on synaptic plasticity and cognitive function
• ✔ Studies of neurodegenerative disease models
• ✔ Preclinical models of learning and memory enhancement

Product Details

Dosage & Usage Guidelines

Reconstitution Protocol

• ✔ Use sterile bacteriostatic water for injection
• ✔ Add appropriate volume to achieve desired concentration
• ✔ Swirl gently to dissolve – do not shake vigorously
• ✔ Store reconstituted solution at 2–8°C

Reconstitute the lyophilized powder using bacteriostatic water to a concentration suitable for your research protocol. The 5 mg format allows for precise dosing across a range of experimental models. Always use aseptic technique during preparation to maintain peptide integrity.

Typical Research Parameters

In research settings, P21 is typically administered via subcutaneous or intraperitoneal injection. Dosing schedules and concentrations vary widely depending on the experimental design, animal model, and specific research objectives.

• ✔ Commonly used in neurogenesis and cognitive function studies
• ✔ Often combined with behavioral and molecular analysis
• ✔ Used to investigate BDNF expression and synaptic plasticity
• ✔ Research models include neurodegeneration and cognitive impairment paradigms

Factors to Consider in Research Protocols

• Lipophilic properties facilitate blood-brain barrier penetration
• Reconstitution stability is limited; prepare fresh solutions for each use
• Individual variation in response may be observed across subjects
• Storage conditions significantly impact peptide stability

Lab Testing & Batch Transparency

Lab status

COA pending release

Third-party analytical testing (COA) for Dragon Pharma P21 5 mg is currently not yet available. Batch-specific assay data, purity analysis, and verification documentation will be published once released.

Testing Status

Pending

COA Availability

Not yet published

Batch Verification

In progress

Update

Coming soon

Transparency note: Dragon Pharma publishes batch-specific lab reports once analytical testing is completed and verified.

Awaiting COA

Shipping & Product Authenticity

What to Expect

• ✔ Orders are processed after payment confirmation
• ✔ USA Domestic shipping is typically faster when local stock is selected
• ✔ International orders include tracking, though update frequency may vary by destination
• ✔ Multiple warehouses may result in separate shipments when applicable

For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.

Storage

Store the lyophilized powder at controlled room temperature (15–25°C) in a dry, dark place, away from direct light and moisture. The unopened vial should be kept in its original packaging to maintain stability.

After reconstitution, store the solution at 2–8°C and use within 14 days. Do not freeze. Discard any unused portion after the recommended storage period. Before use, inspect the solution and avoid use if it appears cloudy, discolored, or contains particulate matter, or if the vial or seal is compromised.

Keep out of reach of children. Follow proper handling and sterile injection practices during research use.

Proper storage conditions help maintain product stability and consistent performance across the product's shelf life.

Frequently Asked Questions